Potassium Citrate and Crystal Light Lemonade

Launched by NORTHWESTERN UNIVERSITY · May 21, 2022

Keywords

ClinConnect Summary

This clinical trial is studying the effects of drinking Crystal Light Lemonade and taking potassium citrate on reducing the risk of kidney stones in people who have a history of these stones and low levels of citrate in their urine. Citrate is a substance that can help prevent stone formation, so the researchers want to see if these two drinks can improve urine conditions to reduce the chances of developing stones again.

To participate in the trial, you need to be between 18 and 80 years old and willing to follow the study's guidelines, which include collecting urine samples for 24 hours during three different times. You should also have low citrate levels or acidic urine based on previous tests. However, if you have certain health issues like severe low citrate levels, uncontrolled diabetes, or allergies to ingredients in Crystal Light, you may not be eligible. Participants can expect to follow a specific plan and contribute to important research that could help others with kidney stones in the future.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • 1. Men and women between age 18-80 years
• • 2. Willing to follow experimental protocol
• • 3. Willing to complete 24-hour urine collections (three total)
• • 4. Willing to sign the informed consent form
• • 5. Completed Litholink Collection with blood work with results
• • a. hypocitraturia OR aciduria i. Hypocitraturics must meet definition of \< 450 mg/day for men \< 550 mg/day for women.
• • b. Low urine pH must be less than 5.6 c. potassium, BUN, creatinine, eGFR and hemoglobin A1c within normal limits
• Exclusion Criteria:
• • 1. Patients with severe hypocitraturia \< 200 mg/day (men or women)
• • 2. Patients with hyperkalemia, uncontrolled diabetes, chronic kidney disease, adrenal insufficiency, delayed gastric emptying (or drug induced delayed gastric emptying), peptic ulcer disease, or active UTI
• • 3. Patients with distal renal tubular acidosis or medication induced RTA (e.g. carbonic anhydrase inhibitor, topiramate)
• • 4. Members of vulnerable patient populations
• • 5. Allergies to ingredients in crystal light
• • 6. Patients lacking decisional capacity